Results 111 to 120 of about 21,372 (208)

Feasibility and Safety of Venetoclax for Cytoreduction During Induction Therapy in Newly Diagnosed Acute Promyelocytic Leukemia

European Journal of Haematology, EarlyView.
ABSTRACT Objective This study aimed to evaluate the feasibility and safety of venetoclax as a cytoreductive strategy during induction therapy in newly diagnosed acute promyelocytic leukemia (APL), and to provide an exploratory description of its early efficacy.
Yu Wang, Rong Xiao, Xiaobing Huang, Yi Xiao   +3 more
wiley   +1 more source

KRAS Mutations Predict Inferior Post‐Remission Outcomes in Newly Diagnosed Acute Myeloid Leukemia With MAPK Pathway Mutations

European Journal of Haematology, EarlyView.
ABSTRACT Somatic mutations in the MAPK signaling pathway are frequently identified at AML diagnosis; however, their impact on treatment resistance and long‐term survival remains unclear. We conducted a retrospective study of patients with newly diagnosed MAPK‐mutated AML seen at the University of Iowa Health Care.
Kensuke Takaoka, Sarah Mott, Ratdanai Yodsuwan, Sakditad Saowapa, Manasawee Tanariyakul, Chalothorn Wannaphut, Kittika Poonsombudlert   +6 more
wiley   +1 more source

Na⁺/H⁺ Exchanger 1 Inhibition Overcomes Venetoclax Resistance in Acute Myeloid Leukemia

Cells
Despite advances with novel targeted agents (e.g., BCL-2 or IDH inhibitors) combined with chemotherapy for acute myeloid leukemia (AML), drug resistance persists.
Shin Young Hyun, Eun Jung Na, Yu Ri Kim, Yoo Hong Min, June-Won Cheong   +4 more
doaj   +1 more source

From infusion to pills in acute myeloid leukaemia: Reorganizing care beyond the infusion unit

British Journal of Haematology, EarlyView.
Fortunato Morabito, Enrica Antonia Martino, Antonella Bruzzese, Nicola Amodio, Santino Caserta, Eugenio Lucia, Virginia Olivito, Caterina Labanca, Francesco Mendicino, Maria Eugenia Alvaro, Ernesto Vigna, Massimo Gentile   +11 more
wiley   +1 more source

Dose‐Adjusted Treatment With 7‐Day Venetoclax Plus Azacitidine or Decitabine in Patients With Acute Myeloid Leukaemia

European Journal of Haematology, EarlyView.
ABSTRACT Acute myeloid leukaemia (AML) in older or unfit patients is commonly treated with hypomethylating agents (HMA) plus venetoclax (VEN), but prolonged VEN exposure often causes substantial haematological toxicity. We retrospectively analysed 61 elderly AML patients treated with HMA + VEN for 7 (7d), 14 (14d) or > 14 days (> 14d) per cycle.
Laurenz Steiner, Lina S. Silva‐Bermudez, Mahmoud Ghazal, Mohammed Abba, Catharina Gerhards, Georgia Metzgeroth, Alice Fabarius, Stefan Klein, Sebastian Kreil, Nanni Schmitt, Patrick Wuchter, Wolf‐Karsten Hofmann, Alexander Streuer   +12 more
wiley   +1 more source

NL101 synergizes with the BCL-2 inhibitor venetoclax through PI3K-dependent suppression of c-Myc in acute myeloid leukaemia

Journal of Translational Medicine
Background Acute myeloid leukaemia (AML) comprises a group of heterogeneous and aggressive haematological malignancies with unsatisfactory prognoses and limited treatment options.
Ying Lu, Xia Jiang, Youhong Li, Fenglin Li, Mengting Zhao, Ye Lin, Lili Jin, Haihui Zhuang, Shuangyue Li, Peipei Ye, Renzhi Pei, Jie Jin, Lei Jiang   +12 more
doaj   +1 more source

Economic Burden of Chronic Lymphocytic Leukaemia in Australia

European Journal of Haematology, EarlyView.
ABSTRACT Background The treatment landscape for chronic lymphocytic leukaemia (CLL) has transformed over the past decade. This study aimed to estimate the healthcare costs and health burden associated with CLL in Australia. Methods A Markov model was developed to simulate the lifetime healthcare costs and health outcomes associated with CLL in ...
Lan Gao, Dieu Nguyen, Victoria White, Patricia M. Livingston, Chan Y. Cheah   +4 more
wiley   +1 more source

CD36‐mediated lipid rewiring in the metabolic adaptation of tumour ecosystems

The FEBS Journal, EarlyView.
Nutrient deprivation drives a lipid‐centric shift in tumour metabolic symbiosis and signalling network. CD36 functions as a bidirectional bridge, transferring fatty acids from stromal donors (adipocytes, CAFs) to the ecosystem tumour‐ and microenvironment‐dependently.
Anna Sebestyén, Viktória Varga, Fatime Szalai, Risa Miyaura, Nóra Förhécz, Bálint Csikós, Rebeka Gelencsér, Zsófia Gábriel, Timea Komlódi, Katalin Dezső, Ildikó Krencz, Dorottya Moldvai   +11 more
wiley   +1 more source

Better Response and Prognosis of Venetoclax Plus Hypomethylating Agents Over Intensive Chemotherapy in Young Adults With Newly Diagnosed ASXL1‐Mutated Acute Myeloid Leukemia

Cancer Medicine
Background ASXL1 is one of the most frequently mutated genes in acute myeloid leukemia (AML) and retains adverse‐risk status in intensively treated cohorts according to 2022 European Leukemia Net (ELN) risk criteria.
Yiming Cai, Jingwen Rui, Zhengwen Ding, Judan Xie, Zhou Jin, Jinyan Xiao, Yang Xu   +6 more
doaj   +1 more source

Tumor Lysis Syndrome with Venetoclax/Carfilzomib/Dexamethasone for Relapsed/Refractory Multiple Myeloma: A Case Report

Reports
Background and Clinical Significance: Tumor lysis syndrome (TLS) is a rare occurrence in patients treated with venetoclax mono- or combination therapy, and clear protocols guiding TLS prophylaxis are lacking.
Reilly Fankhauser, Alan Lu, Adetola Kassim, Eden Biltibo   +3 more
doaj   +1 more source